Mesothelioma Law BlogAsbestos-Laden Structure Threatens State Fair Community An old, vacant building where the Naval and Marine Corps reserve building used to stand is a concern to the State Fairgrounds says the Pueblo Telegraph, in Pueblo, Colorado. An assessment showed that airborne asbestos is present around the building. Fearing the serious health effects of asbestos,... Read More at the Mesothelioma Blog Couple Files Mesothelioma Lawsuit against 73 Companies An elderly couple from North Carolina is going after 73 companies. Sidney William Mauney and his wife claims in a recently filed lawsuit that these companies were aware and should have informed that asbestos is hazardous to their health. Mauney was exposed to asbestos-containing products during his... Read More at the Mesothelioma Blog |
Home : Environmental Toxins : Mesothelioma : Law Articles : New and Promising Research May Help Mesothelioma Patients New and Promising Research May Help Mesothelioma PatientsMesothelioma is one of the most aggressive forms of cancer, and it has limited treatment options. While radiation and chemotherapy can help relieve patients' symptoms, the cancer often metastasizes leaving patients with a poor prognosis. For example, those who are diagnosed with stage III or greater are usually only given about six months to a year to live. The reason for so little treatment options is because by the time someone is diagnosed, they have already reached the later stages, where it is too late. Unfortunately, many who are diagnosed with mesothelioma do not show or experience symptoms of the disease for up to thirty years after initial exposure. The main cause of contracting the cancer is exposure to asbestos. When asbestos fibers are inhaled, ingested, or tampered with, the fibers become lodged in the lining of the heart, lung and abdomen, causing inflammation which, in turn, causes mesothelioma. However, malignant mesothelioma patients may have hope in a few years if researchers in Great Britain can prove the effectiveness of a vaccine in pancreatic cancer patients. According to researchers at Liverpool University, the "TeloVac jab" is part of a new set of drugs "use the body's own defenses to fight cancer, stopping tumors in their tracks." Over 1,000 men and women who are in the late stages of pancreatic cancer are participating in the study. While the results are not available yet, many in the study are claiming that the drug has added years their lives. Earlier trials showed the vaccine adding an average of three months to late-stage pancreatic cancer patients. The vaccine works by forcing the body's immune system to kill an enzyme called telomerase, which is present in cancer cells, allowing them to grow uncontrollably. Coordinator of the clinical trial and professor of Liverpool University, Professor Neoptolemos, said that the result “is like the immune system has a blindfold on and the vaccine takes the blindfold off.” The researchers hope that the vaccine will be effective against other types of cancer like, lung, liver, and skin cancers. Their hope is that the vaccine will result in a truly universal vaccine that can be used for all types of cancer. Several clinical trials, including one from the Memorial-Sloan Cancer center, have been conducted in hopes of finding a vaccine for those who have been exposed to asbestos. For more information about other clinical trials, please visit LegalView's mesothelioma clinical trials web page. Find a Mesothelioma Lawyer Now
This form is secure and encrypted. More information about secure forms and your privacy here.
|




